Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 25 of 25 results for crizotinib

  1. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

    Discontinued [GID-TA10625]

    Technology appraisal guidance
    Discontinued

  3. HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)

    NICE has developed a medtech innovation briefing (MIB) on HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer .

    Medtech innovation briefing
    Published
    7 November 2017

  4. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

    Medtech innovation briefing
    Published
    8 January 2018

  5. Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

    Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults.

    Technology appraisal guidance
    Published
    18 May 2022
    View recommendations

    Sections for TA789

  6. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA584

  7. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1021.

    Technology appraisal guidance
    Published
    4 July 2018

  8. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Technology appraisal guidance
    Published
    25 September 2013

  9. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic

    Diagnostics guidance
    Published
    14 August 2013
    View recommendations

    Sections for DG9

  10. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence